Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743109 | 0.92 | FOLH1 (0.57) | RXRAMRGPRX4ATMMAPTMAPK1 | |
| SCHEMBL6451155 | 0.86 | RXRA (0.57) | RXRAMRGPRX4ATMMAPTKDM4E | |
| SCHEMBL15709508 | 0.85 | RXRA (0.54) | RXRAMRGPRX4ATMMAPTKDM4E | |
| SCHEMBL4600081 | 0.85 | RXRA (0.54) | RXRAMRGPRX4ATMMAPTKDM4E | |
| SCHEMBL2580651 | 0.84 | KMT2A (0.56) | RXRAMRGPRX4ATMMAPTNPC1 | |
| SCHEMBL6358665 | 0.83 | MAOB (0.56) | RXRAMRGPRX4MAPTHTR1AADRA1D | |
| SCHEMBL11464594 | 0.83 | FOLH1 (0.52) | RXRAMRGPRX4ATMMAPTMAPK1 | |
| SCHEMBL2387474 | 0.82 | NPC1 (0.56) | RXRAMRGPRX4MAPTHTR1ANPC1 | |
| SCHEMBL1030218 | 0.82 | CA12 (0.65) | MAPTKDM4EALDH1A1MAPK1TDP1 | |
| SCHEMBL4696202 | 0.81 | MAPK1 (0.55) | KDM4EALDH1A1MAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-7138527-B2 | Inflammatory, allergic and respiratory disorders; beta 2 adrenoceptors agonists; such as 5-(-2-((-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl)amino)propyl) -N-(2-methoxybenzyl)-1H-indole-2-carboxamide | PFIZER INC. (US) | 2006-11-21 | — | — | US | disclosed |
| CN-1723020-A | Indole derivatives as beta-2 agonists | PFIZER LTD (US) | 2006-01-18 | — | — | CN | disclosed |
| EP-1556034-A1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | BROWN ALAN D (GB) | 2005-04-21 | — | — | US | disclosed |
| US-6844362-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1440966-A1 | Indole derivatives useful for the treatment of diseases | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040116503-A1 | Indole derivatives useful for the treatment of diseases | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004032921-A1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | IDO1, IDO2, INMT | RXRA 3284/4885MRGPRX4 359/4885ATM 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.